Roivant Sciences (ROIV) Cash & Equivalents (2021 - 2026)

Roivant Sciences has reported Cash & Equivalents for 6 years, with the latest figure at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 47.73% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (down 47.73% YoY), and the FY2026 full-year result was $1.4 billion, down 47.73% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.4 billion, down from $1.5 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $6.7 billion in Q4 2023, with the low at $99.1 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $2.4 billion across 5 years, with a median of $1.6 billion in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 98.51% — and 2025, when it jumped 1391.95%.
• Roivant Sciences' Cash & Equivalents stood at $1.5 billion in 2022, then jumped by 336.73% to $6.7 billion in 2023, then tumbled by 98.51% to $99.1 million in 2024, then jumped by 1391.95% to $1.5 billion in 2025, then fell by 3.99% to $1.4 billion in 2026.
• The last three Cash & Equivalents figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.